Baxter (BAX) –
-
Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
-
Form S-1/A Nuwellis, Inc.
-
Baxter (BAX) Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
-
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
-
Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
-
Form PRE 14A Nuwellis, Inc. For: May 10
-
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
-
Baxter International (BAX) PT Raised to $44 at Citi
-
Baxter (BAX) Announces FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software
-
Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
-
Form DEFA14A BAXTER INTERNATIONAL
-
Baxter to Host Annual Meeting of Stockholders in Virtual Format
-
Form 8-K Nuwellis, Inc. For: Mar 26
-
Form DEFA14A BAXTER INTERNATIONAL
-
Form DEF 14A BAXTER INTERNATIONAL For: May 07
-
Form 8-K BAXTER INTERNATIONAL For: Mar 21
-
Form PRE 14A BAXTER INTERNATIONAL For: May 07
-
Form S-1/A Nuwellis, Inc.
-
Form 10-K Nuwellis, Inc. For: Dec 31
-
Form 4 BAXTER INTERNATIONAL For: Mar 06 Filed by: Toth Christopher A.
-
Form 4 BAXTER INTERNATIONAL For: Mar 06 Filed by: Stevens Brian
-
Form 4 BAXTER INTERNATIONAL For: Mar 06 Filed by: Sonig Alok
-
Form 4 BAXTER INTERNATIONAL For: Mar 06 Filed by: Rosenbloom David S.
-
Form 4 BAXTER INTERNATIONAL For: Mar 06 Filed by: Mason Jeanne K
-
Form 4 BAXTER INTERNATIONAL For: Mar 06 Filed by: Rasul Reazur
-
Form 4 BAXTER INTERNATIONAL For: Mar 06 Filed by: Borzi James W
-
Form 4 BAXTER INTERNATIONAL For: Mar 06 Filed by: Knight Heather
-
Form 4 BAXTER INTERNATIONAL For: Mar 06 Filed by: ALMEIDA JOSE E
-
Form 4 BAXTER INTERNATIONAL For: Mar 06 Filed by: Grade Joel T.
-
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
-
Form 4 BAXTER INTERNATIONAL For: Mar 04 Filed by: Stevens Brian
-
Form 4 BAXTER INTERNATIONAL For: Mar 04 Filed by: Rasul Reazur
-
Form 4 BAXTER INTERNATIONAL For: Mar 04 Filed by: Knight Heather
-
Form 4 BAXTER INTERNATIONAL For: Mar 04 Filed by: Borzi James W
-
Form 4 BAXTER INTERNATIONAL For: Mar 04 Filed by: Mason Jeanne K
-
Form 4 BAXTER INTERNATIONAL For: Mar 04 Filed by: ALMEIDA JOSE E
-
Form 8-K Nuwellis, Inc. For: Mar 05
-
Form 4 BAXTER INTERNATIONAL For: Mar 01 Filed by: Rosenbloom David S.
-
Form 4 BAXTER INTERNATIONAL For: Mar 01 Filed by: Sonig Alok
-
Form 4 BAXTER INTERNATIONAL For: Mar 01 Filed by: Stevens Brian
-
Form 4 BAXTER INTERNATIONAL For: Mar 01 Filed by: Knight Heather
-
Form 4 BAXTER INTERNATIONAL For: Mar 01 Filed by: Mason Jeanne K
-
Form 4 BAXTER INTERNATIONAL For: Mar 01 Filed by: Borzi James W
-
Form 4 BAXTER INTERNATIONAL For: Mar 01 Filed by: ALMEIDA JOSE E
-
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
-
Baxter International (BAX) PT Raised to $45 at BofA Securities
-
Form 8-K BAXTER INTERNATIONAL For: Mar 04
-
Form 144 BAXTER INTERNATIONAL Filed by: Mason Jeanne K
-
Baxter to Present at Raymond James 45th Annual Institutional Investors Conference
-
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
Back to BAX Stock Lookup